These results demonstrate that SCGB3A2 is an anti-fibrotic agent, and suggest a possible therapeutic use of recombinant SCGB3A2 in the treatment of pulmonary fibrosis. This evidence concerns the gene SCGB3A2 and pulmonary fibrosis.